Literature DB >> 24658395

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.

Steen Husted1, Raffaele de Caterina, Felicita Andreotti, Harald Arnesen, Fedor Bachmann, Kurt Huber, Jørgen Jespersen, Steen Dalby Kristensen, Gregory Y H Lip, Joao Morais, Lars H Rasmussen, Agneta Siegbahn, Robert F Storey, Jeffrey I Weitz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658395     DOI: 10.1160/TH14-03-0228

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  34 in total

1.  Stroke prevention in atrial fibrillation: Where are we now?

Authors:  Gregory Y H Lip
Journal:  Indian Heart J       Date:  2015-11-28

2.  Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation.

Authors:  Qinmei Xiong; Gregory Y H Lip
Journal:  Curr Treat Options Neurol       Date:  2015-02       Impact factor: 3.598

Review 3.  Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Authors:  Boris Arbit; Jonathan C Hsu
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

Review 4.  The role of oral anticoagulant therapy in patients with acute coronary syndrome.

Authors:  Jae Youn Moon; Deepa Nagaraju; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Ther Adv Hematol       Date:  2017-10-13

Review 5.  Safety and efficacy of prothrombin complex concentrate (PCC) for anticoagulation reversal in patients undergoing urgent neurosurgical procedures: a systematic review and metaanalysis.

Authors:  Harrison Faulkner; Shubham Chakankar; Marco Mammi; Jack Yu Tung Lo; Joanne Doucette; Nawaf Al-Otaibi; Judi Abboud; Andrew Le; Rania A Mekary; Adomas Bunevicius
Journal:  Neurosurg Rev       Date:  2020-10-03       Impact factor: 3.042

6.  Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.

Authors:  Marion Ferner; Daniel Wachtlin; Torsten Konrad; Oliver Deuster; Thomas Meinertz; Stephan von Bardeleben; Thomas Münzel; Monika Seibert-Grafe; Günter Breithardt; Thomas Rostock
Journal:  Clin Res Cardiol       Date:  2015-06-25       Impact factor: 5.460

Review 7.  Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.

Authors:  Rigas G Kalaitzidis; Anila Duni; Georgios Liapis; Olga Balafa; Sofia Xiromeriti; Paulos Karolos Rapsomanikis; Moses S Elisaf
Journal:  Int Urol Nephrol       Date:  2017-02-04       Impact factor: 2.370

Review 8.  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Authors:  Adam Cuker; Deborah M Siegal; Mark A Crowther; David A Garcia
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094

9.  Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.

Authors:  Marco Proietti; Valeria Raparelli; Brian Olshansky; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2015-11-02       Impact factor: 5.460

10.  Acute Pulmonary Embolism: Contemporary Approach to Diagnosis, Risk-Stratification, and Management.

Authors:  Tahir Tak; Swetha Karturi; Umesh Sharma; Lee Eckstein; Joseph T Poterucha; Yader Sandoval
Journal:  Int J Angiol       Date:  2019-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.